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ABSTRACT
Introduction: The Rehabilitation EnAblement in
CHronic Heart Failure in patients with Heart Failure (HF)
with preserved ejection fraction (REACH-HFpEF) pilot
trial is part of a research programme designed to
develop and evaluate a facilitated, home-based, self-
help rehabilitation intervention to improve self-care and
quality of life (QoL) in heart failure patients and their
caregivers. We will assess the feasibility of a definitive
trial of the REACH-HF intervention in patients with
HFpEF and their caregivers. The impact of the REACH-
HF intervention on echocardiographic outcomes and
bloodborne biomarkers will also be assessed.
Methods and analysis: A single-centre parallel two-
group randomised controlled trial (RCT) with 1:1
individual allocation to the REACH-HF intervention plus
usual care (intervention) or usual care alone (control)
in 50 HFpEF patients and their caregivers. The REACH-
HF intervention comprises a REACH-HF manual with
supplementary tools, delivered by trained facilitators
over 12 weeks. A mixed methods approach will be
used to assess estimation of recruitment and retention
rates; fidelity of REACH-HF manual delivery;
identification of barriers to participation and adherence
to the intervention and study protocol; feasibility of
data collection and outcome burden. We will assess
the variance in study outcomes to inform a definitive
study sample size and assess methods for the
collection of resource use and intervention delivery
cost data to develop the cost-effectiveness analyses
framework for any future trial. Patient outcomes
collected at baseline, 4 and 6 months include QoL,
psychological well-being, exercise capacity, physical
activity and HF-related hospitalisation. Caregiver
outcomes will also be assessed, and a substudy will
evaluate impact of the REACH-HF manual on resting
global cardiovascular function and bloodborne
biomarkers in HFpEF patients.
Ethics and dissemination: The study is approved
by the East of Scotland Research Ethics Service (Ref:
15/ES/0036). Findings will be disseminated via
journals and presentations to clinicians,
commissioners and service users.
Trial registration number: ISRCTN78539530;
Pre-results .
INTRODUCTION
Epidemiological data show that approxi-
mately half of those patients with clinical fea-
tures of heart failure (HF) have preserved
ejection fraction population (HFpEF).1 2
Strengths and limitations of this study
▪ Design of study to inform the feasibility of defini-
tive trial.
▪ Assessment of facilitated home-based self-
management intervention in heart failure.
▪ Intervention that involves caregivers and evalu-
ation of caregiver outcomes.
▪ Single centre study limiting external
generalisability.
▪ No definitive evaluation of intervention clinical
and cost-effectiveness.
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Patients with HFpEF are generally older, more often
women, have a higher prevalence of hypertension, dia-
betes and atrial fibrillation and are less likely to have cor-
onary artery disease than those with HF with reduced
ejection fraction (HFrEF).1 3 However, the substantial
burden from HFpEF appears to be similar to that from
HFrEF, measured by exercise intolerance, poor
health-related quality of life (HRQoL), mortality, increased
hospital admissions and higher healthcare costs.4–6
Although there has been increasing success of
pharmacological and device therapy to improve out-
comes in HFrEF, prognosis in HFpEF remains
unchanged, with no individual large-scale randomised
controlled trial (RCT) demonstrating significant treat-
ment benefits.7 Although no pharmacological therapy
has been shown to reduce mortality in HFpEF, pharma-
cological therapy of HFpEF does demonstrate quantifi-
able improvements in exercise capacity.7
Systematic reviews and meta-analyses have shown
promising evidence for the benefit of exercise-based
cardiac rehabilitation (CR) in HFpEF.8 9 The most
recent meta-analysis of 6 RCTs in 276 patients found
exercise-based CR significantly improved exercise cap-
acity and HRQoL compared to usual care.9
Notwithstanding that this evidence base consists of small
RCTs of short follow-up (typically follow-up of 6-months
or less); there were two other important limitations.
First, there remain uncertainties in the mechanism of
action in exercise-based CR interventions for HFpEF; no
significant changes have been observed in the systolic or
diastolic function with exercise-based CR in HFpEF
patients. Second, the CR programmes undertaken in
these RCTs were predominantly supervised and deliv-
ered in centre-based settings. There is increasingly rec-
ognition for the possibility of alternative delivery models
of CR, such as telehealth and home-based programmes
in order to overcome suboptimal rates of CR uptake
seen with HF.10 European research indicates that only a
minority of eligible HF patients are receiving exercise-
based CR.11
The Rehabilitation EnAblement in CHronic Heart
Failure (REACH-HF) programme of research was
designed to develop and evaluate a health professional
facilitated home-based self-help rehabilitation interven-
tion to improve self-care and HRQoL in people with HF
and their caregivers.12
A core element of the REACH-HF intervention is exer-
cise training which will be invested to better understand
the mechanisms by which exercise intervention can
improve exercise tolerance in HFpEF. In HFrEF patients,
exercise intervention has been shown to improve cardio-
respiratory fitness though cardiac13 14 and extra cardiac
mechanisms.15 16 The cardiac mechanisms include
reverse left ventricular remodelling17 and improvement
in diastolic function.18 19 The ability of exercise interven-
tions to improve early diastolic relaxation has also been
shown in elderly individuals20 and in patients after a
myocardial infarction with a pre-existent abnormal
relaxation pattern. Diastolic dysfunction is an important
feature of exercise intolerance in patients with HFpEF.21
Despite this, little is known about the impact of exercise
training on diastolic function in HFpEF. This study will
allow the opportunity to assess diastolic function and LV
filling in more detail to better understand mechanisms
of exercise intervention in HFpEF. As bloodborne bio-
markers can offer objective and biologically relevant and
mechanistic insights that complement the findings of
echocardiographic measurements, we propose to
measure biomarkers of distinct mechanisms that contrib-
ute to the pathophysiology of HF.
AIM
The overarching aim is to assess the feasibility of a
definitive trial of the clinical and cost-effectiveness of
the REACH-HF intervention in patients with HFpEF.
Specific aims of the study were to estimate recruitment
and retention of participants (patients and caregivers);
and to evaluate components of the study process: feasi-
bility of outcome data collection processes, and outcome
burden and completion/attrition rates for participants
(patients and caregivers). Specific objectives of the study
were (1) to collect views of participants (patients and
caregivers) on acceptability of the study design; (2) to
assess the feasibility and experience of the addition of
the REACH-HF intervention to usual care for partici-
pants (patients and caregivers) and intervention facilita-
tors; (3) to identify barriers to participation and
adherence to the intervention and study procedures; (4)
to inform a definitive study sample size by assessment of
the variance in study outcomes; (5) to assess methods
for the collection of data on resource use and costs asso-
ciated with the delivery of the intervention; (6) to
develop the framework for cost-effectiveness analyses for
any future full trial and economic evaluation; (7) to
assess the fidelity of REACH-HF manual delivery by
intervention facilitators and (8) to undertake a mechan-
istic substudy using echocardiographic and bloodborne
biomarkers.
METHODS AND ANALYSIS
This protocol is reported in accord with the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) 2013 guidance for protocols of clinical
trials.22
Design
A parallel two-group randomised controlled pilot trial
with individual participant allocation to the intervention
or control group with a nested mixed methods feasibility
evaluation and mechanistic substudy. Participants will be
individually randomised to either the intervention
group (REACH-HF intervention plus usual care) or the
control (usual care alone) group. The design is depicted
in figure 1.
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Setting
The study will be conducted in a single investigator
centre in one Scottish Health Board. In order to achieve
adequate participant enrolment to sample size, the site
can recruit via a number of secondary care pathways: HF
disease/research registers; outpatient cardiology, HF and
cardiovascular risk clinics: medicine for the elderly
clinics; or CR services. Recruitment performance will be
formally reviewed periodically by the central trial man-
agement team. Follow-up procedures will usually be con-
ducted on NHS premises. Conduct of the study will be
led by a local principal investigator (supported by a coin-
vestigator), research nurse/fellow and a research assist-
ant (for qualitative elements); all of whom are trained
in Good Clinical Practice and in the requirements of the
study protocol. The site is responsible for the recruit-
ment and scheduled follow-up visits of participants.
Study population
The study population includes patients and their
caregivers. Participating patients will be aged 18 years
or older and have a confirmed diagnosis of HFpEF
on echocardiography (preferable), radionuclide
ventriculography or angiography (ie, left ventricular
ejection fraction ≥45% within the last 6 months prior to
randomisation). Patients who have undertaken CR
within 6 months prior to enrolment will be excluded, as
will patients with a contraindication to exercise testing
or exercise training (with consideration of adapted
European Society of Cardiology guidelines for HF).23
The full list of patient inclusion and exclusion criteria is
listed in box 1.
Participating caregivers will be aged 18 years or older
and provide unpaid support to participating patients
who could otherwise not manage without such support.
Unpaid support includes emotional support, prompting
with taking medications, observing for signs and symp-
toms of HF, getting prescriptions, encouraging participa-
tion in social events and physical activity, helping with
household tasks or providing physical care.
A patient may still participate if s/he does not have an
identified caregiver, or if the patient’s caregiver is not
willing to participate.
Participants are free to withdraw from the study at any
time, without any negative impact to their ongoing care.
If a participant chooses to withdraw, their reason for
Figure 1 Consort flow chart.
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withdrawal will be noted where possible. Any data col-
lected on participants prior to withdrawal will be
retained for analysis.
Randomisation
Participants will be randomly allocated in a 1:1 ratio to
either intervention or control group arms without strati-
fication or minimisation. Randomisation numbers will
be computer generated and assigned in strict sequence.
At the point of randomisation, participants will be
assigned the next randomisation number in the
sequence. To maintain concealment and minimise selec-
tion bias, randomisation will be performed after the
baseline visit by a member of Peninsula Clinical Trials
Unit (CTU), independent from investigator teams,
using a secure, web-based randomisation system.
Intervention
The REACH-HF intervention is grounded in the support
needs and priorities of people living with HF and the
services that provide care for them. A systematic, six-step
intervention mapping framework guided intervention
development,24 drawing on research evidence, national
and international guidelines and stakeholder consulta-
tions with patients, caregivers and health professionals
to identify ‘targets for change’. In line with intervention
mapping, regulatory processes underpinning target
behaviour patterns and evidence-based change techni-
ques were matched to each behaviour-change target.25 A
key element of the intervention development process
was an active patient and public involvement (PPI)
group consisting of six people with a range of experi-
ences with HF and three caregivers of people with HF.
The intervention development process is described in
detail elsewhere.26 Development of a facilitated self-care
and rehabilitation intervention for people with HF and
their care givers; Rehabilitation Enablement in Chronic
Heart Failure (REACH-HF). Submitted for publication,
November 2015).
The REACH-HF intervention is a comprehensive self-
care support programme comprising the ‘Heart Failure
Manual’ (REACH-HF manual), with a choice of two
exercise programmes for patients, a ‘Family and Friends
Resource’ for caregivers, a ‘Progress Tracker’ tool for
patients and a 3-day training course for intervention
facilitators.
Participating patients and caregivers will work through
the REACH-HF manual over a 12-week period with facili-
tation by a specially trained intervention facilitator
(cardiac nurse by background), who will help to build
the patient’s and caregiver’s understanding of how to
manage HF. The REACH-HF manual includes informa-
tion and interactive elements covering a wide range of
topics relating to living with/adapting to living with HF
and includes four core elements:
1. an exercise training programme, tailored according
to initial fitness assessments, delivered as a walking
programme or a chair-based exercise DVD, or a com-
bination of the two (as selected by the patient);
2. managing stress /breathlessness /anxiety;
3. heart failure symptom monitoring (and associated
help-seeking);
4. understanding HF and taking medications.
The REACH-HF manual was originally designed for
patients with HFrEF (ejection fraction <45%). There was
limited evidence to guide the development of the
REACH-HF manual for HFpEF patients; it has been
adapted for this pilot study to allow evaluation in patients
with HFpEF (ejection fraction ≥45%). The section on
medications has been revised to make it relevant to
HFpEF patients, and an additional section has been
added on the nature of causes and treatment of HFpEF.
The majority of the self-care advice in all other sections
of the REACH-HF manual is relevant to all patients with
HF and corresponds to national HF guidelines.27 28
Patients will be advised to use the Progress Tracker,
which is designed to encourage patients to monitor
their own condition over the period of the intervention
and to make associations between improvements in self-
care and improvements in symptoms/well-being. It
includes sections in which patients can record changes
in physical and mental state, intensity of exercise and
self-reported walking speed, physical activity, engage-
ment in enjoyable activities, frequency of self-weighing
(to monitor fluid build-up) and frequency of use of
stress-management techniques. The Family and Friends
Resource, a manual for use by caregivers, includes
advice on providing support for a person with heart
failure, becoming a caregiver, managing the caregiver’s
own health and well-being and getting help.
Intervention delivery may be discontinued at any time
at the request of a participant or by the intervention
facilitator if the intervention is no longer deemed appro-
priate, for example, altered clinical condition.
Adherence by facilitators to the intervention protocols
will be measured through fidelity assessment.
Usual care
In accord with findings of our national survey,29 HF
patients typically do not receive CR, despite national
recommendations.28 The choice of a usual care (no CR)
comparator in this therefore reflects of the current situ-
ation for the vast majority of HF patients in UK.
Intervention and control group patients will receive
usual medical management for HF according to national
and local guidelines. Data related to health service
usage and medication use will be captured at each
follow-up through participants’ completion of health-
care resource use questionnaires and by collection of
concomitant medication usage as reported by
participants.
Outcome measures
Outcome data will be collected at 4 and 6 months post-
randomisation (table 1). The 4-month time point
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coincides with the planned end of the 3-month inter-
vention delivery period for participants in the interven-
tion arm. This allows a 1-month period after the
baseline visit for completion of randomisation and refer-
ral processes.
Pilot trial outcome measures
The feasibility of a definitive trial will be determined by
collection and analysis of the following pilot study
outcome measures.
▸ Recruitment rate for participants (patients and care-
givers) across the various recruitment pathways
▸ Attrition and loss to follow-up at 4 and 6 months
postrandomisation
▸ Completion and completeness of main trial outcome
measures at follow-up
▸ Fidelity of REACH-HF manual delivery by interven-
tion facilitators (for details of the methods used, see
the ‘Process Evaluation’ section)
▸ Acceptability of the intervention to HFpEF patients,
their caregivers and facilitators (for details, see the
‘Process Evaluation’ section)
▸ Acceptability of study participation to participants.
Main trial outcome measures
The following outcomes proposed for a future definitive
trial will be collected in this pilot trial:
▸ Primary outcome measure for HF patients
Patients’ disease-specific HRQoL measured using the
Minnesota Living with Heart Failure questionnaire
(MLHFQ).30
▸ Secondary outcome measures for HF patients will
include:
– Composite outcome of death or hospital admission
related to HF or not related to HF.
– N-terminal Brain Natriuretic Peptide (NT-pro-BNP)
levels.31
– Exercise capacity (incremental shuttle walking test
ISWT).32
– Physical activity level (GeneActive accelerometry
over a 7-day period).33
– Psychological well-being using Hospital Anxiety and
Depression Scale (HADS) questionnaire.34
– Generic HRQoL using the EQ-5D-5L
questionnaire.35
– Disease-specific HRQoL using the Health Related
Quality of Life (HeartQoL) questionnaire.36
– Self-care of HF Index questionnaire (SCHFI).37
– Self-efficacy for key behaviours questionnaire (devel-
oped by the research team).
– Healthcare usage (primary and secondary care con-
tacts, social care contacts and relevant medication
usage, reported by patient participants).
– Safety outcomes.
Patients who are unable or not willing to undertake
the exercise capacity assessment will not be excluded;
Box 1 Trial entry criteria
Inclusion criteria
1. Male or female aged ≥18 years
2. Patients with heart failure, defined by the presence of at least
one of the following symptoms at the time of screening:
▸ paroxysmal nocturnal dyspnoea
▸ or orthopnoea
▸ or dyspnoea on mild or moderate exertion
AND at least one of the following signs prior to study entry:
▸ basal crepitations
▸ or elevated jugular venous pressure
▸ or lower extremity oedema
▸ or chest radiograph demonstrating pleural effusion, pulmonary
congestion or cardiomegaly.
3. Patients with left ventricular ejection fraction (EF) ≥45%
obtained within 6 months prior to randomisation and after any
myocardial infarction (MI) or other event that would affect EF
(ideally obtained by echocardiography, although radionuclide ven-
triculography and angiography are acceptable).
4. Provision of informed consent to participate.
Exclusion criteria
1. Patients who have undertaken cardiac rehabilitation (CR) within
the last 6 months
2. Patients with severe chronic pulmonary disease defined as
requiring home oxygen or hospitalisation for exacerbation within
12 months or significant chronic pulmonary disease in the
opinion of the investigator.
3. Patients who have any of the following contraindications to
exercise testing or exercise training documented in their medical
notes:
▸ Early phase after acute coronary syndrome (up to 2 days)
▸ Untreated life-threatening cardiac arrhythmias
▸ Acute heart failure (during the initial period of haemodynamic
instability)
▸ Uncontrolled hypertension (systolic blood pressure (SBP)
>200 and/or diastolic blood pressure (DBP) >100)
▸ Advanced atrioventricular block
▸ Acute myocarditis and pericarditis
▸ Symptomatic aortic stenosis
▸ Severe hypertrophic obstructive cardiomyopathy
▸ Acute systemic illness
▸ Intracardiac thrombus
▸ Progressive worsening of exercise tolerance or dyspnoea at
rest over previous 3–5 days
▸ Significant ischaemia during low-intensity exercise (<2 meta-
bolic equivalents, <50 W)
▸ Uncontrolled diabetes (blood glucose >16 mmol/L or HbA1C
>9% or equivalent unit)
▸ Recent embolism
▸ Thrombophlebitis
▸ Recent-onset atrial fibrillation/atrial flutter (in the last 4 weeks)
4. Patients who are unable to understand the study information or
unable to complete study procedures.
5. Patients who are in a long-term care establishment or who are
unwilling or unable to travel to research assessments or accom-
modate home visits.
6. Patients judged to be unable to participate in the study for any
other reason, for example, psychiatric disorder, diagnosis of
dementia, life-threatening comorbidity.
7. Patients participating in concurrent interventional research
which may overburden the patient or confound data collection.
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these patients will start on the lower levels of the chair-
based exercise or walking programme.
For caregivers a series of measures will be captured
which include:
▸ Caregiver Burden Questionnaire—HF (CBQ-HF).38
▸ Caregiver Contribution to Self-care of HF Index ques-
tionnaire (CC-SCHFI).37
▸ Family Caregiver Quality of Life Scale questionnaire
(FAMQOL).39
▸ Generic HRQoL using the EQ-5D-5L questionnaire.35
▸ Psychological well-being using HADS questionnaire.34
Given the nature of the REACH-HF intervention, it is
not possible to blind participants or those involved in
the provision of care. Researchers undertaking
collection of outcome data and the statistician undertak-
ing the data analysis will be blinded to treatment alloca-
tion in order to minimise potential bias. As part of the
4-month and 6-month data collection, the researchers
undertaking collection of outcome data will confirm
whether or not any inadvertent unblinding occurred
during the clinic visit.
Sample size
We aim to recruit 50 patient participants (25 interven-
tion: 25 control). This number will allow us to achieve
the feasibility aims and objectives of this study, that is, an
estimate of attrition (mean 20%, 95% CI of 23%), esti-
mates of the SD of the primary and secondary outcome
Table 1 Tabulated summary of study schedule
Postrandomisation
TIME POINT
Baseline
t0 Randomisation
+4 months
t1
+6 months
t2
ENROLMENT:
Eligibility screen X
Informed consent X
Demographics X
Medical History X
Randomisation* X
INTERVENTIONS:
Intervention group:
Usual care
REACH-HF manual facilitation†
Control group:
Usual care
ASSESSMENTS:
MLHFQ Questionnaire X X X
SCHFI Questionnaire X X X
HADS Questionnaire X X X
Heart-QOL Questionnaire X X X
EQ-5D-5L Questionnaire X X X
Self-efficacy for key behaviours questionnaire X X
Trial process questionnaire X
CC-SCHFI Questionnaire (caregivers) X X X
CBQ-HF Questionnaire (caregivers) X X X
FAMQOL Questionnaire (caregivers) X X X
HADS Questionnaire (caregivers) X X X
EQ-5D-5L Questionnaire (caregivers) X X X
Trial process questionnaire (caregivers) X
Resource Use Data Collection X X X
Echocardiography X X
Blood sample for NT-pro-BNP X X
Blood sample for bloodborne biomarkers X X
Incremental Shuttle Walk Test X X X
Accelerometry X X X
SAFETY MONITORING:
Adverse event reporting
*Randomisation will be performed by the Peninsula Clinical Trials Unit (CTU), typically within 10 days of the baseline clinic, following receipt
of baseline data and blood sample result.
†REACH-HF manual facilitation will start ∼1 month postrandomisation.
CBQ-HF, The Caregiver Burden Questionnaire for HF; CC-SCHFI, Caregiver Contribution to Self-care of HF Index questionnaire; FAMQOL,
Family Caregiver QoL questionnaire; HADS, Hospital Anxiety and Depression Scale questionnaire; HF, heart failure; MLHFQ, Minnesota
Living with HF questionnaire; pro-BNP, pro-brain natriuretic peptide; QoL, quality of life; SCHFI, Self-care of HF Index questionnaire.
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measures and sufficient numbers of patients to under-
take qualitative interviews to assess feasibility and accept-
ability of study design and intervention. It is estimated
that a total of 216 patients would be needed for a defini-
tive trial to detect a clinically meaningful between group
difference in the primary outcome of MLHFQ (for
details of this sample size calculation, see ref. 12). No
sample size calculation has been applied to the caregiver
participants. A previous RCT in CR indicates a ratio of
caregivers to patients of 0.6–0.7:1.0,40 therefore it is
expected that between 30 and 35 caregivers will be
recruited in this pilot.
Trial data collection
Trial data are collected from trial participants (patients
and caregivers) during three clinic visits (at baseline, 4
and 6 months). In order to encourage participant reten-
tion and completeness of data, participants may claim
travel expenses associated with clinic visits and are pro-
vided with postage-paid envelopes to return question-
naires by post. Participants who are unwilling or unable
to travel to research assessments or accommodate home
visits are excluded at the point of consent.
At the baseline clinic visit, after written informed
consent has been obtained by the principal investigator
or authorised delegate, the following information will be
collected:
▸ medical history (including comorbidities (number
and severity scored with Charlson comorbidity
index), New York Heart Association class, HF aeti-
ology, concomitant HF medication and presence of
implantable HF devices);
▸ healthcare resource usage over the prior 6 months;
▸ sociodemographic information (ie, date of birth, eth-
nicity, weight, employment status, education level,
smoking status).
Participating patients will be asked to:
▸ complete a booklet comprising the primary and sec-
ondary outcome questionnaires;
▸ perform an incremental shuttle walking test;
▸ undergo echocardiography examination at rest;
▸ provide two blood samples (∼4 mL blood sample for
measurement of NT pro-BNP level and ∼4 mL for
the analysis of bloodborne biomarkers);
▸ wear a wrist-worn accelerometer for 8 days.
Participating caregivers will also be asked to provide
sociodemographic information (ie, age (date of birth),
ethnicity, weight, employment status, education level,
smoking status) and to complete a booklet comprising
the caregiver outcome questionnaires.
At the 4-month and 6-month clinic visits investigators
will record details of any changes to patients’ HF medica-
tion or implantable cardiac devices, details of any hospita-
lisations and healthcare resource usage since the previous
visit. Investigators will also check that participating patients
have not developed contraindications to exercise testing
before conducting the incremental shuttle walking tests.
The echocardiography examinations at rest will be
conducted at baseline and 6 months, unless an appropri-
ate echocardiography examination has been conducted
within 2 weeks prior to the clinic visit, and the patient
agrees to the data being used for the study.
Echocardiographic measurements will include diastolic
and systolic parameters. Blood samples collected for deter-
mination of NT pro-BNP levels) will be dispatched to a
central laboratory (Royal Cornwall Hospital NHS Trust).
Blood samples collected for the analysis of bloodborne
biomarkers will be analysed at the recruiting site.
Biomarkers of distinct mechanisms that contribute to the
pathophysiology of HF will be measured (growth differen-
tiation factor 15 (GDF15); ventricular remodelling
(soluble ST2); myonecrosis (highly sensitive troponin T
(hsTnT)) and wall stress (NT-pro-BNP)).41 Accelerometer
devices will be worn for 8 days then returned by partici-
pants using postage-paid to the CTU for data extraction.
Participant safety will be monitored through recording,
reporting and review of all serious adverse events collected
from baseline until final follow-up visit.
Data collected at clinic visits will be recorded on study-
specific case report forms (CRFs) by the research team
at each site. Completed CRFs will be checked and
signed at the research sites by a member of the research
team before being sent to the CTU. Original CRF pages
and completed questionnaire booklets will be posted to
the CTU at agreed time points for double-data entry in
to the study database. Accelerometer data will be
imported directly into the study database. All forms and
data will be tracked using a web-based trial management
system. Double-entered data will be compared for dis-
crepancies according to a data management plan held
in CTU. Discrepant data will be verified using the ori-
ginal paper data sheets.
Separate participant contact details will be retained
for the purpose of managing intervention delivery and
follow-up interviews. Investigators will ensure that the
participants’ anonymity is maintained on all other docu-
ments. Within the CTU, anonymised and identifiable
study data will be stored separately, to prevent the iden-
tification of participants from research records, in
locked filing cabinets within a locked office. Data will
be collected and stored in accordance with the Data
Protection Act 1998. Electronic records will be stored
by the CTU in a secure and Secure Sockets Layer
(SSL) encrypted web-based database maintained by
the University of Plymouth with daily back up. Direct
access to the trial data will be restricted to members of
the research team and the CTU, with access granted to
the sponsor on request and overseen by the CTU data
manager and trial manager.
Process evaluation
Alongside the main patient and carer follow-up, a
process evaluation will be completed using a nested
mixed methods design to assess the following elements
of the intervention.
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Intervention fidelity
A 13-item intervention fidelity checklist developed and
piloted as part of the REACH-HF programme will be
used to assess fidelity of delivery of the intended inter-
vention processes.12 The checklist is based on a Dreyfus
Scale which has been used to assess clinical competence
in the delivery of psychological therapies,42 as well as in
other self-care behaviour interventions.43 All contacts
(telephone and face to face) between intervention facili-
tators and six purposively sampled patient will be audio
recorded by intervention facilitators and then reviewed
and coded (using the fidelity checklist) by two inde-
pendent researchers. This will clarify how well interven-
tion components are delivered and received and will
also allow researchers to describe variability in fidelity of
delivery across patients and facilitators.
Acceptability of the intervention to HFpEF patients, their
caregivers and facilitators
A series of semistructured individual interviews will be
conducted with ∼15 patients and their caregivers (where
available) at the end of the intervention delivery period
(∼4 months from baseline visit). Using an interview
schedule, the researcher will explore participants’
experiences of the REACH-HF intervention and the
acceptability of study participation. Purposive sampling
will be used to ensure maximal variation in relation to
clinical and demographic characteristics, caregiver
involvement and engagement with the intervention.
The facilitators who have delivered the intervention
will be interviewed individually by either the interven-
tion development team or the Dundee-based researcher
after the majority of participants have completed the
intervention. A topic guide has been developed for this
study, informed by the REACH-HF feasibility study.44
In addition, all participants (patients and caregivers)
will be invited to complete a ‘Trial Process’ question-
naire at the end of their participation in which their
views and comments on various aspects of the study will
be captured.
A facilitator contact sheet will be completed for each
patient contact to record basic attendance at each
contact and contact time. The contact sheet will also ask
the intervention facilitator to make notes immediately
after the patient contact about what was covered, what
went well in the session; what worked less well; what s/
he could have performed differently and what we could
improve about the intervention materials or the delivery
process. The importance of completing these sheets was
emphasised in the facilitator training session.
Economic evaluation
In this pilot study, we will estimate the additional
resource use and related costs, associated with the deliv-
ery of the intervention, and assess the methods used to
collect participant level data on healthcare services used
and other related resource use. Data on these areas of
resource use will be collected within trial, using reported
input by intervention facilitators, and self-report (inter-
viewer administered) participant resource use question-
naires (eg, primary and community healthcare,
hospital-based healthcare). In any future economic
evaluation, alongside a full trial, the primary perspective
of the evaluation is expected to be that of factors related
to collecting clinical and resource-use data within the
trial will be evaluated. The primary perspective will be
that of the UK NHS and personal social services (consist-
ent with the reference case approach used in the UK by
NICE),45 with a broader perspective, addressing partial
patient and societal resource use, explored in sensitivity
analyses. That will therefore be the guiding perspective
for data collection in the current pilot study perspective.
Informed by CRFs, methods for estimating the resource
use and costs associated with delivery of the intervention
will be developed and tested. Alongside the data collec-
tion on resource use, consideration will be given to out-
comes, including the anticipated primary economic end
point of the EQ-5D-5L35 and to the development of the
framework for future within trial and longer term cost-
effectiveness analyses.
Data analysis
All analyses, quantitative and qualitative, will be con-
ducted according to best practise and reported in
accordance with Consolidated Standards of Reporting
Trials (CONSORT) guidelines for reporting of clinical
trials and appropriate guidelines for reporting process
evaluations and qualitative research.46–48
Pilot study outcomes
Given the feasibility objectives of this pilot study, the
focus of data analysis will be descriptive. The partici-
pant flow will be summarised using the CONSORT
flow diagram, reporting detailed recruitment and attri-
tion rates (treatment and study drop-outs) with 95%
CIs. All protocol deviations along with reasons and
number of missing items on questionnaires will be
reported.
Intervention fidelity checklist scores will be sum-
marised using simple descriptive statistics (means and
SDs) and collated as an overall total score, individual
item scores and (total and item) scores for each facilita-
tor. Examples of good practice will be flagged, tran-
scribed and extracted as audio clips or transcripts (with
the facilitator’s permission) to inform future training.
Checklist items will be scored for each recording.
Participant interview data will be analysed using
descriptive, thematic analysis to identify salient themes
from the interview transcripts. The data will be analysed
with the aim of addressing the study aim and the study
objectives, that is, to seek the views of patients, caregivers
and facilitators on the acceptability of intervention
manual and/or the intervention delivery processes and
to collect the views of patients and caregivers on the
study design.
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Primary, secondary and economic outcomes
Baseline sociodemographic and health-related variables
will be reported descriptively by treatment arm. For all
the primary and secondary outcome variables, we will
report descriptive statistics only (total number of obser-
vations available, with mean and SD, or median and
IQR, as appropriate), at baseline, 4-month follow-up and
6-month follow-up. All analyses will be conducted by a
statistician who is blinded to treatment allocation and
will be performed on an intention-to-treat, complete
case basis. Given the pilot nature of the study, we will
report levels of missing of data (and reasons for loss)
but we will not undertake any imputation analyses.
While we do not seek to formally estimate cost-
effectiveness in this pilot study, estimates of interven-
tion cost will inform exploratory modelling and esti-
mates of the resources and costs needed to run a
future trial. In any future definitive RCT, cost-
effectiveness analysis is expected to involve within trial
analysis and evidence synthesis with decision-analytic
modelling, to assess the longer term consequences of
the intervention (eg, changes in outcomes, events
avoided, life-years and quality-adjusted life-years
gained). It is expected that this modelling will use/
adapt existing economic models on outcomes for HF,
and the subsequent cost-effectiveness of interventions.
This pilot study will be used to consider how best to
construct such analyses and to develop an economic
evaluation plan for any future definitive RCT.
Data monitoring and quality assurance
The site principal investigators (CCL, KS) or
authorised delegate(s) will check completed CRFs for
missing data or obvious errors before the forms are
sent to the CTU. Data will be monitored centrally for
quality and completeness by the CTU, and every effort
will be made to recover data from incomplete forms
where possible.
The CTU data manager will oversee data tracking and
data entry and initiate processes to resolve data queries
where necessary. The CTU trial manager(s) (CH and
VE) will devise a monitoring plan specific to the study
which will include central monitoring strategies and
study site visits as appropriate. The participating site will
be required to permit the CTU trial manager or deputy,
or representative of the sponsor, to undertake study-
related monitoring to ensure compliance with the
approved study protocol and applicable standard operat-
ing procedures (SOPs), providing direct access to source
data and documents as requested. All study procedures
will be conducted in compliance with the protocol and
according to the principles of the International
Conference on Harmonisation Good Clinical Practice
(ICH GCP). Procedures specifically conducted by the
CTU team (eg, data management, study management
and study monitoring) will be conducted in compliance
with CTU SOPs.
Trial management and independent committees
Team members directly involved with the day-to-day
running of the trial at site will meet regularly to discuss
trial progress, teleconferencing with external members
of the REACH-HF management team on a monthly
basis with email and telephone exchange as necessary
between. The Programme Management Group includ-
ing health economics, statistics, process evaluation and
patient and public representation will meet on a quar-
terly basis to review status of the overall programme,
including trial progress.
The REACH-HF Programme Steering Committee
(Chair: Professor Martin Cowie and four other independ-
ent members including a patient and public involvement
representative) have formally agreed to adopt the role of
Trial Steering Committee and will oversee the conduct of
the trial with safety and ethics review by a fully independ-
ent Data Monitoring Committee (Chair: Dr Ann-Dorthe
Zwisler and two other independent members). Evidence
for treatment differences in the main efficacy outcome
measures will not be monitored through review of accu-
mulating outcome data, and no interim data analyses will
be conducted.
The Trial Steering Committee and Data Monitoring
Committee meet one to two times per year. Detailed
descriptions of the remit and function of the oversight
committees are documented in specific charters held in
the Trial Master File by CTU.
The Independent Adjudication Committee (Professor
Ian Squire (Chair), De Sern Lim and Dr Francisco
Levya) will independently assess all hospitalisations and
deaths of patient participants during the study for their
relatedness to HF in accordance with the study-specific
procedure.
ETHICS AND DISSEMINATION
The study will be conducted in accordance with the
ethical principles that have their origin in the
Declaration of Helsinki and that are consistent with ICH
GCP and in accordance with the Research Governance
Framework for Health and Social Care, Second edition
(2005). The study is sponsored by Royal Cornwall
Hospitals NHS Trust (Research Development and
Innovation Department, Royal Cornwall Hospital,
Treliske, Truro, Cornwall, TR1 3LJ). Written informed
consent will be obtained from all participants prior to
study enrolment. Participants enrolled into the study are
covered by indemnity for negligent harm arising from
the management, design and conduct of the research
through standard NHS Indemnity arrangements. The
study is approved by the East of Scotland Research
Ethics Service (ref 15/ES/0036). Any subsequent
amendments will be made using the Integrated
Research Applications System in order to maintain
ethical approval and NHS permissions. Amended docu-
ments will be provided to the investigator site by CTU.
In the event of changes to study design requiring
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significant amendment to the content of the participant
information sheet, participants will be required to
provide renewed informed consent.
The ISRCTN number was granted on 7 July 2015 fol-
lowing significant correspondence between the Trials
Unit, the permissions team in Scotland and the South
West Peninsula CRN team, with regard to the ISRCTN
registration. The first participant was randomised on 2
July 2015 in good faith by the trial team following green
light from the sponsor. It took 1 month to ascertain that
the UKCRN was unable to support an ISRCTN registra-
tion and that the sponsor would need to apply and pay
independently, as the study was not going to be network
adopted. The 5-day period between randomisation and
ISRCTN registration accounts for 1 patient out of a
planned 50 patient sample size. No changes to any trial
procedures or protocol were made during or as a result
of this recruitment period and the trial protocol was
already registered with the Trust, sponsor and ethics
committee.
Findings will be published in peer-reviewed journals
and presented at local, national and international meet-
ings and conferences to publicise and explain the
research to clinicians, commissioners and service users.
A final report will be submitted to the National Institute
for Health Research which will be available on request
to any interested others.
CONCLUSIONS
This pilot trial aims to assess the feasibility of a definitive
trial of the clinical effectiveness and cost-effectiveness of
the REACH-HF intervention (a manualised home-based
rehabilitation intervention designed to improve self-care
and HRQoL) in patients with HFpEF and their caregivers.
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